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Introduction
Menaquinone-7 (MK-7) is part of a family of vitamin K, 
micronutrients necessary for the synthesis of blood coag-
ulation factors and the activation of proteins involved in 
the building of bones and inhibition of vascular calcifi-
cation (Cranenburg et al., 2007; Shearer and Newman, 
2008).
The vitamin K consists of two main subfamilies: vita-
min K1 (phylloquinone) and vitamin K2 or menaquino-
nes. All the K vitamins have a similar structure; they share 
a “quinone” ring and an isoprenoid side chain. The differ-
ence lies in the side chain. Menaquinones are classified 
according to the length of their aliphatic side chain and 
are designated MK-n, where n represents the number of 
isoprenoid residues in that chain (Booth and Suttie, 1998; 
Shearer and Newman, 2008). Thus, MK-7 contains seven 
isoprenoid units. The vitamins K are highly lipophilic; 
MK-7 being more lipophilic than K1 and MK-4, resulting 
in a much longer half-life (Schurgers and Vermeer, 2002; 
Schurgers et al., 2007).
Vitamin  K  plays  a  critical  role  as  a  co-factor  for 
γ-glutamyl  carboxylase-catalyzed  reactions  in  the 
posttranslational  carboxylation  of  glutamic  acid  to 
γ-carboxy  glutamic  acid,  and  both  vitamin  K1  and 
K2 function in this way (Shearer and Newman, 2008). 
These γ-carboxy glutamate (Gla) residues form calci-
um-binding sites that are essential for the activity of 
the proteins in which they are found (Rishavy et al., 
2004).  Gla-containing  proteins  are  found  in  bone, 
and for this reason vitamin K may play an additional 
role in the homeostasis of bone metabolism and con-
tribute  to  bone  health  (Binkley  et  al.,  2002;  Knapen 
et  al.,  2007;  Bügel,  2008;  Shea  and  Booth,  2008),  as 
well  as  play  a  role  in  reducing  fracture  incidences 
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in  postmenopausal  women  (Cockayne  et  al.,  2006; 
Iwamoto  et  al.,  2006;  Cheung  et  al.,  2008;  Iwamoto 
et al., 2009). In this respect, dietary intake of fermented 
soybean (natto), which is rich in MK-7, has been asso-
ciated  with  reduced  bone  loss  in  postmenopausal 
women (Ikeda et al., 2006). Interestingly, recent data 
also point to a role of menaquinones and especially 
the  higher  menaquinones,  such  as  MK-7,  in  reduc-
ing  the  incidences  of  coronary  heart  disease  (CHD) 
(Geleijnse et al., 2004; Beulens et al., 2009; Gast et al., 
2009). Vitamin K1, however, was not shown to have 
any impact on CHD.
Natto-derived  MK-7  is  produced  by  Bacillus  subtilis 
natto and consists of all-trans MK-7 (Sato et al., 2001), and 
we were able to produce a synthetic MK-7. Considering the 
lack of standard toxicological testing on MK-7, the objec-
tive of the present study was to determine the safety of 
MK-7 produced by synthetic means. The potential toxicity 
of MK-7 was assessed in an acute oral toxicity test in mice 
and in a subchronic toxicity study in rats following daily 
oral administration for 90 days (with inclusion of groups 
allowed to recover for 30 days after the end of dosing).
Materials and methods
Test materials
Synthetic  all-trans  MK-7  (molecular  weight:  649.0; 
molecular formula: C46H64O2) was obtained from Kappa 
Bioscience AS (Oslo, Norway) (produced by Synthetica 
AS, Oslo, Norway) and is named KB-MK-7 (previously 
designated as SynMK-7). The MK-7 test article was a 
yellow powder with 95% to 97% purity (three batches) 
and  was  characterized  by  mass  spectrometry  (MS), 
infrared  (IR)  spectroscopy,  high-performance  liquid 
chromatography (HPLC)/ultraviolet (UV) light analy-
sis (270 nm), and nuclear magnetic resonance (NMR). 
The characteristics of MK-7 are given in Table 1. The 
product is light-sensitive, and thus, all stock suspen-
sions/solutions and dosing formulations in the acute 
and subchronic toxicity studies were prepared in the 
dark either under gold-source fluorescent illumination 
(wavelength   520 nm)  or  in  a  darkened  room  with 
minimal exposure to regular fluorescent lighting. In the 
subchronic toxicity study, all MK-7 stock solutions and 
dosing formulations were stored protected from light 
at 2°C to 8°C. The vehicle control was stored under the 
same conditions as the MK-7 dosing formulations.
Sunflower oil was obtained from Sigma for use as the 
vehicle  in  the  acute  toxicity  study.  Corn  oil  was  used 
as the vehicle in the subchronic toxicity study and was 
obtained  from  Professional  Compounding  Centers  of 
America (PCCA, Houston, TX).
Acute oral toxicity study in female mice
The acute oral toxicity study was conducted in accordance 
with  the  Organisation  for  Economic  Cooperation  and 
Development (OECD) Test Guideline 425 for the Testing 
of Chemicals (The Limit Test). The study protocol was 
approved by the Norwegian Animal Research Authority 
and the study was performed at The Norwegian Institute 
of  Public,  Department  of  Laboratory  Animal  Service 
Unit, Oslo, Norway, in compliance with the European 
Convention for the Protection of Vertebrate Animals Used 
for Experimental and Other Scientific Purposes (ETS No. 
123, 1986). The study was performed in the spirit of Good 
Laboratory Practice (GLP).
Preparation of dosing formulation
MK-7 was dissolved in sunflower oil to a nominal work-
ing concentration of 200 mg/mL. The MK-7 dosing sus-
pension was prepared fresh and delivered to the animal 
facility on the day of use. The test substance was heated 
in a water bath of ~37°C and was transparent and clear 
without  particulates  upon  aspiration  and  dosing.  The 
Table 1.  Technical and chemical description of synthetic menaquinone-7 (MK-7).
Technical and chemical description of synthetic MK-7
Chemical name(s) (all-E)-2-(3,7,11,15,19,23,27-Heptamethyl-2,6,10,14,18,22,26-octacosaheptaenyl)-3-methyl-1,4-naphthalenedione
Synonyms Vitamin MK- 7, Menaquinone-7, Menaquinone 7, Vitamin K2 (35), MK-7
CAS number 2124-57-4
Chemical structure O
O
Molecular formula C46H64O2
Molecular weight 649 g/mol
Appearance Yellow powder
Odor Odorless
Melting point 54°C
Boiling point 720.1°C at 760 mm Hg
Flash point 254.9°C
Density 0.961 g/cm3
Solubility Insoluble in water
Purity (HPLC) ≤95% all-trans MK-7522  K. Pucaj et al.
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MK-7 dosing suspension was protected from light until 
aspiration into the dosing syringe. The results for calcu-
lated dose concentrations of vitamin MK-7 in sunflower 
oil were within ±10% of the target dose, quantified using 
a reversed phase (HPLC-UV) assay method.
Animals and treatment
Nulliparous  and  non-pregnant  female  BomTac:NMRI 
mice were obtained from Taconic (Ry, Denmark), and 
were 8 weeks at the start of the study. Five animals out of 
the available seven animals were randomly selected at 
study start with weight as the limiting factor. The animals 
were specific pathogen-free according to the Federation 
of  European  Laboratory  Animal  Science  Associations 
guidelines  and  were  clinically  examined  upon  arrival 
and identified by ear marking. The animals were allowed 
an acclimatization period of 6 days after delivery and 
before  they  entered  the  study.  They  were  housed  in 
standard type III macrolon cages in a Scantainer cabi-
net under controlled temperature and light conditions 
(22 ± 3°C,  40–70%  relative  humidity,  12-h  light  phase 
with daylight) with ad libitum access to SDS RM1 diet 
(Special Diet Services, UK) and municipal water (food 
was temporarily withdrawn for 1–2 h prior to oral gavage 
on Day 0). Nestpak aspen tree bedding (Datesand Ltd., 
UK) and cage enrichment (plastic igloos) were used. The 
animals were housed in groups of 3 or 4 per cage during 
acclimatization and until the day of dosing. The animals 
were housed as single animals during the first 48 h after 
dosing. Following the 48-h observation period for ani-
mals 2 to 5, all animals were returned to their original 
groups and the animals were housed in groups of three 
or four animals for the remainder of the 14-day observa-
tion period.
The animals were monitored for the first 30 min after 
dosing and twice daily on the day of dosing. Observations 
were done once daily thereafter for the remainder of the 
14-day observation period. In addition to mortality or kill-
ing of animals for humane welfare reasons, observations 
included clinical signs indicative of changes from normal-
ity with respect to skin, fur, eyes, mucous membranes, and 
respiratory, circulatory, autonomic, and central nervous 
systems. Animals were also observed for changes in motor 
activity and behavior pattern. The mice were sacrificed by 
cervical dislocation at the end of the observation period.
MK-7  was  administered  by  oral  gavage,  using  a 
stainless steel gavage needle. The animals were dosed 
with 10 mL/kg body weight of the supplied suspension, 
corresponding  to  a  dose  of  2000 mg/kg  body  weight 
(based  on  a  target  concentration  of  200 mg/mL). 
Animal number 1 was dosed first and animals 2 to 5 
were dosed 48 h later. The day of dosing was designated 
as Day 0 and animals were weighed at Days 0, 7, and 14 
(termination).
Observations
The animals were monitored twice daily on the day of 
dosing  and  once  daily  thereafter  for  the  remainder  of 
the  14-day  observation  period.  Observations  included 
changes  in  skin,  fur,  eyes,  mucous  membranes,  and 
respiratory, circulatory, autonomic, and central nervous 
systems.  Animals  were  also  observed  for  changes  in 
motor activity and behavior pattern. The mice were sacri-
ficed by cervical dislocation at the end of the observation 
period.
The 90-day subchronic toxicity study in rats
The 90-day toxicity study was performed in accordance 
with the United States Food and Drug Administration 
(U.S.  FDA)  regulations  on  GLP  for  Nonclinical 
Laboratory  Studies  (Title  21,  Part  58  of  the  Code  of 
Federal Regulations) and with the OECD Principles of 
GLP. The study design was based on the principles of the 
current test guidelines for repeated-dose toxicity studies 
as issued by the U.S. FDA, OECD (Test Guideline 408), 
Health Canada (Therapeutics Product Directorate), and 
the International Conference on Harmonisation (ICH) 
[Guideline M3(R2)]. The study was conducted at Nucro-
Technics,  Toronto,  ON,  Canada.  The  GLP  compliance 
of this 90-day study as attested by the signatures of the 
Study Director and the Institutional Quality Assurance 
Unit indicated that the methods, results, and data con-
tained in the 90-day study report accurately reflect the 
procedures followed and raw data collected during the 
study.
Preparation of dosing formulations
For the 90-day subchronic toxicity study, the MK-7 test 
article was produced according to Good Manufacturing 
Practice (GMP). Dosing formulations, consisting of a 
stock solution of 2.0 mg/mL MK-7 in corn oil and stock 
solution dilutions of 1.0 and 0.5 mg/mL MK-7 in corn 
oil, were prepared every 3 to 4 days and aliquoted daily 
prior to use. The purity of the test article was taken into 
account during preparation. The mean dosing concen-
trations of dosing formulations prepared on Days 1, 30, 
59, and 90 were analytically determined by LC/MS/MS 
to be within 92.5 ± 4.6%, 92.5 ± 4.6%, and 95.9 ± 8.7% of 
the nominal concentrations for the 0.5, 1, and 2 mg/mL 
dose formulations, respectively. During dose admin-
istration, all MK-7 dosing formulations were continu-
ally mixed on a stir plate and protected from light until 
aspiration into the dosing syringe. The corn oil vehicle 
control  was  aliquoted  and  handled  under  the  same 
conditions.
Animals and treatment
Animals used in this study were acclimatized for 3 weeks 
and treated and cared for in accordance with the guide-
lines recommended by the Canadian Council on Animal 
Care  (CCAC)  and  the  Association  for  Assessment  and 
Accreditation of Laboratory Animal Care International 
(AAALAC),  and  the  experimental  protocol  for  treating 
the animals was approved by the Institutional Animal 
Care Committee of Nucro-Technics under the Protocol 
number: 220117.AUP. A total of 70 male and 71 female Synthetic vitamin K2, menaquinone-7, toxicology  523
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Sprague-Dawley rats (Rattus norvegicus), aged 4–5 weeks, 
were obtained from Charles River Canada Inc., Montreal, 
PQ. Each animal was identified with a unique tail tattoo. 
At the start of dosing, males weighed between 259 and 
329 g and females weighed between 190 and 227 g. The 
rats were housed individually in Nalgene® rat cages with 
stainless steel cage covers under controlled conditions: 
temperature of 18°C to 26°C, relative humidity of 30–70%, 
a minimum of 10 air changes per hour, and a 12-h light 
and 12-h dark cycle. The animals were provided Teklad 
Certified  Rodent  Diet  (#8728C)  and  municipal  water 
(using water bottles) ad libitum. All contaminants in the 
feed and water were confirmed to be within acceptable 
ranges. On arrival, all rats were subjected to a general 
physical examination by a qualified technician to ensure 
that they were free of disease. Animals were acclimated 
over  a  21-day  period,  during  which  time  they  were 
observed for clinical signs of disease. In addition, a health 
screen was performed on five male and five female rats 
that were randomly selected from the rat colony. At the 
end of the acclimatization period, all remaining rats were 
found to be healthy and 50 rats of each sex were random-
ized into four groups using randomization statistical soft-
ware. Each group consisted of 10 rats of each sex with an 
additional five rats/sex allotted to the control and high-
dose recovery groups.
Animals  were  administered  MK-7  at  a  dose  of  0 
(vehicle corn oil only), 2.5 (low-dose), 5.0 (mid-dose), or 
10.0 mg/kg body weight/day (high-dose) by oral gavage 
for 90 consecutive days. The dosing volume administered 
to each animal was 5 mL/kg body weight, adjusted based 
on the animal’s most recent body weight. The dose lev-
els were chosen based on the anticipated daily dose in 
humans and on the results from the 28-day dose range 
finding  study  in  which  no  compound-related  adverse 
effects were observed at doses of up to 10 mg/kg body 
weight/day.
Clinical observations, body weights, and food consumption
Animals were monitored closely after dosing, and were 
observed  for  clinical  signs  and  mortality  twice  daily 
throughout the study. Animals were observed for reac-
tion to treatment such as changes in skin, fur, eyes, and 
mucous  membranes.  Respiratory,  circulatory,  auto-
nomic, central nervous system, somatomotor activity, 
and behavior patterns were also monitored along with 
any  other  signs  of  ill-health.  Detailed  clinical  signs 
were recorded once a week, with examination of gen-
eral appearance, respiration, abnormalities of behavior 
and movement, external organs, skin, and any lesions. 
A functional observation battery (FOB) assessment for 
motor  activity,  grip  strength,  and  sensory  activity  to 
visual, audio, and proprioceptive stimuli was conducted 
on all animals during the last week of dosing and on 
recovery animals during the last week of the study.
Body weights were recorded during the acclimatiza-
tion period (Days −19, −12, and −5), on the first day of 
administration (Day 1) prior to dosing, and then weekly 
thereafter.  End  of  treatment  body  weights  (unfasted) 
were recorded on Day 90. Terminal body weights of main 
study rats were recorded prior to necropsy on Day 91 or 
92 following an overnight fast. Body weights of recovery 
animals were recorded on Days 1, 8, 15, 22, 30, and prior 
to necropsy (fasted) on Day 31 of the recovery period 
(Day 121 of the study). Body weight changes (unfasted) 
were calculated. Food consumption was recorded during 
the acclimatization period and weekly until scheduled 
necropsy.
Funduscopic  (indirect  ophthalmoscopy)  and  bio-
microscopic (slit lamp) examinations were performed 
on all animals ~2 weeks prior to the start of treatment 
and  on  all  main  study  and  recovery  rats  on  Day  87. 
Ophthalmoscopy was not conducted at the end of the 
recovery period, as there was no indication of ophthal-
mic toxicity in rats examined at the end of the treatment 
period.
Clinical pathology
Blood samples were collected on Day 44 from five male 
and five female rats (fasted) by orbital sinus or jugular 
bleeds and limited clinical pathology (hematology and 
clinical  chemistry)  performed.  Blood  samples  were 
also  collected  on  the  day  of  necropsy  from  all  main 
study and recovery animals following an overnight fast. 
Blood was obtained from the abdominal aorta following 
anesthesia induced by isoflurane and routine clinical 
pathology investigations performed. Hematology was 
performed on EDTA-treated samples and parameters 
measured included red blood cell (RBC) count, hemat-
ocrit, hemoglobin, white blood cell (WBC) count, WBC 
differential,  mean  corpuscular  hemoglobin  (MCH), 
MCH concentration (MCHC), mean corpuscular vol-
ume (MCV), mean platelet volume, cell morphology, 
platelet  count,  and  reticulocyte  count.  Coagulation 
was  determined  from  citrate-treated  samples  and 
parameters  measured  included  activated  partial 
thromboplastin  time  (APTT)  and  prothrombin  time 
(PT). Clinical chemistry was performed on serum and 
included total protein, albumin, globulin (calculated), 
albumin/globulin  (A/G)  ratio,  alanine  aminotrans-
ferase  (ALT),  alkaline  phosphatase  (ALP),  aspartate 
aminotransferase (AST), γ-glutamyl transferase (GGT), 
lactate  dehydrogenase  (LDH),  creatine  kinase  (CK), 
total bilirubin, blood urea nitrogen (BUN), creatinine, 
fasting  glucose,  total  cholesterol,  triglycerides,  cal-
cium, chloride, inorganic phosphorus, potassium, and 
sodium. Hematology and clinical chemistry data were 
compared with the laboratory’s baseline historical data 
for Sprague-Dawley rats.
Urine was collected overnight (approximately a 12-h 
period) by placing rats in metabolic cages during the last 
weeks of dosing and recovery. Animals were fasted dur-
ing urine collection. The urine samples were analyzed for 
color, appearance, volume, pH-specific gravity, bilirubin, 
urobilinogen, blood, glucose, ketones, leukocytes, nitrite, 
and sediment microscopy.524  K. Pucaj et al.
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Pathology
On Day 91 (males) or 92 (females), following an overnight 
fast (~12 h), all surviving main study animals were anes-
thetized  by  exposure  to  isoflurane,  exsanguinated,  and 
subjected  to  necropsy.  Recovery  animals  were  treated 
similarly on Day 31 of the recovery period. Necropsies con-
sisted of an external examination, including reference to all 
clinically recorded lesions, and a detailed internal exami-
nation. Organs that were collected and weighed included 
the adrenals, ovaries, brain, pituitary gland, epididymis, 
prostate, heart, spleen, kidneys, thymus, liver, testes, lungs, 
and uterus (horns, cervix, and body). Paired organs were 
weighed together, and absolute and relative weights (rela-
tive to terminal body weight and brain weight) were calcu-
lated. The following organs and tissues were also collected: 
aorta  (thoracic),  cecum,  colon,  duodenum,  esophagus, 
ileum,  jejunum,  liver  (sample  of  central  and  left  lobes), 
lymph  nodes  (mandibular  and  mesenteric),  mammary 
glands (inguinal), salivary glands (submandibular), semi-
nal  vesicles,  sciatic  nerve,  skeletal  muscle  (quadriceps), 
skin  (inguinal)  and  subcutis,  spinal  cord,  sternum  and 
marrow, stomach, thyroid/parathyroids, and urinary blad-
der. Organs and tissues were fixed in 10% neutral buffered 
formalin, except for the eyes, optic nerves, and testes, which 
were fixed in alcoholic formalin, paraffin-embedded, sec-
tioned, and stained with hematoxylin and eosin. Full histo-
pathological examination was performed on tissues from 
control and high-dose animals, as well as on tissues with 
abnormal findings from all dose groups.
Statistical analysis
For the 90-day toxicity study homogeneous data were 
analyzed using the analysis of variance (at P  =  0.05), and 
the significance of intergroup differences were analyzed 
using Duncan’s or other appropriate test. Heterogeneous 
data  were  analyzed  using  the  Kruskal–Wallis  test  and 
the significance of intergroup differences between the 
control and treated groups were assessed using Dunn’s 
or other appropriate test. T-test was conducted on the 
recovery rats.
Results
Acute oral toxicity study in mice
At the limit dose level of 2000 mg/kg body weight, MK-7 
did not induce any signs of toxicity in any of the treated 
mice following dosing and during the 14-day observation 
period. In addition, the body weight gain of treated mice 
was not adversely affected. Two non-treated animals were 
included as a reference. Based on these results and under 
the conditions of this study, the median lethal dose (LD50) 
of MK-7 was determined to be greater than the limit dose 
level of 2000 mg/kg body weight in BomTac:NMRI mice.
The 90-day subchronic toxicity study in rats
Clinical observations, body weights, and food consumption
All  animals  from  the  main  study  and  recovery  groups 
survived the course of the study with no clinical signs of 
systemic toxicity or abnormalities in neurological func-
tion. Alopecia was observed in one low-dose and one high-
dose female, the latter of which also displayed reduced 
body weight gain. Both animals were otherwise healthy 
with no other abnormalities noted in all other parameters 
assessed. One male rat of the low-dose group presented 
with clinical signs (dyspnea, piloerection, and lameness), 
reduced  food  consumption,  and  loss  in  body  weight, 
which were attributed to a procedural injury, consisting of 
deposition of the test article in the periesophageal tissue. 
Consequently, an abscess had formed in the left upper 
thorax region (confirmed at necropsy and histopathology 
examination), which was surgically drained on Day 70 
following an 8-day suspension of test article administra-
tion. Body weight gain was subsequently observed in this 
animal. Additionally, inclusion of this animal in the group 
food consumption, body weight, and body weight gain 
results did not result in statistically significant differences 
compared with the control group.
At  the  end  of  the  dosing  period,  ophthalmological 
examinations revealed corneal–subepithelial crystalline 
opacity in all groups, including the control group, with 
similar frequency and severity among groups. Cataracts 
were also noted in groups administered MK-7; however, a 
dose-dependent response was not observed. All ophthal-
mological observations were within historical ranges for 
the strain and age of rats.
All  groups  displayed  satisfactory  body  weight  gains 
and no significant differences in body weights or body 
weight  gains  were  observed  between  the  control  and 
MK-7 test groups (Figures 1 and 2). Food consumption 
was also not significantly different between the control 
and MK-7 test groups (data not shown). Water consump-
tion, monitored daily by visually observing water levels 
in bottles, did not appear to differ between groups (actual 
water consumption was not measured).
Clinical pathology
Significant differences in hematology results included an 
increase in MCV in mid-dose females at mid-study (Day 
44) and an increase in hematocrit in high-dose males of 
the recovery group compared with control rats (data not 
shown). These changes were neither dose- nor time-de-
pendent, were not observed at any other time point or in 
the opposite sex, and were slight in magnitude. No other 
significant  differences  in  hematology  were  observed 
between the control and MK-7 test groups. At mid-study, 
several  parameters  in  various  groups,  including  con-
trol animals, were slightly above the upper limit of the 
normal ranges, with no dose-dependency observed. At 
the end of the dosing and recovery periods, the results 
of  all  hematology  parameters  examined  were  within 
normal baseline historical ranges in all groups (data not 
shown).
Coagulation time group summaries are presented in 
Table 2. A significant increase in APTT was observed in 
female rats of the mid- and high-dose groups at the end 
of the dosing period compared with the control group. Synthetic vitamin K2, menaquinone-7, toxicology  525
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The  change  in  APTT  was  resultant  of  two  rats  in  the 
mid-dose group and one rat in the high-dose group with 
elevated APTT times (i.e. the two female rats from the 
mid-dose group had APTT values of 29.2 sec and 29.6 sec 
and the high-dose female had an APTT value of 38.8 sec). 
When these rats were removed from the calculations, the 
APTT was comparable among all groups, with no statis-
tically significant differences. A similar change was not 
observed in male rats and the mean PT and APTT were 
within the normal physiological limits at the end of the 
dosing and recovery periods in all groups.
Clinical chemistry results revealed a few incidental sig-
nificant differences between control and MK-7 test groups 
at mid-study and at the end of the dosing period as shown 
in Table 3. These changes were neither dose- nor time-
dependent, were observed at only one time point, and 
were, for the most part, observed in one sex only. These 
changes were typically within the normal ranges, with a 
few significantly different results that were very slightly 
above the upper limit of the normal ranges in female rats 
at the mid-study point only. Some other values, including 
those of the control group, were also observed to be at the 
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Figure 2.  Body weight of Sprague-Dawley female rats as a function of time following administration of menaquinone-7 (MK-7) in the 
90-day subchronic toxicity study. Each value represents the mean of 10 animals.
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Figure 1.  Body weight of Sprague-Dawley male rats as a function of time following administration of menaquinone-7 (MK-7) in the 90-day 
subchronic toxicity study. Each value represents the mean of 10 animals.526  K. Pucaj et al.
  Toxicology Mechanisms and Methods
high or low end of the physiological range, but without 
dose- or time-dependency. Apart from a significant, yet 
slight, increase in serum calcium concentration in high-
dose males, no significant differences were observed in 
clinical chemistry results compared with controls at the 
end of the recovery period in either males or females 
(data not shown). Urinalysis results were also unremark-
able, with no differences observed between control and 
MK-7 test groups (data not shown).
Pathology
Organ weights and organ to body and brain weight ratio 
summaries are presented in Table 4. No significant dif-
ferences  in  absolute  or  relative  organ  weights  were 
observed between male control and MK-7 test groups at 
the end of the dosing and recovery periods. In female rats 
administered MK-7, the following significant differences 
were observed compared with control females at the end 
of the dosing period: a decrease in absolute and relative 
(to body and brain weight) ovary weight in the mid-dose 
group and an increase in lung weight relative to brain 
weight in the high-dose group. At the end of the recov-
ery  period,  the  following  significant  differences  were 
observed in the high-dose female group: a decrease in 
absolute and relative (to body and brain weight) thymus 
weight, a decrease in relative (to brain weight) spleen 
weight, and an increase in brain weight relative to body 
weight. No dose-dependent relationship was observed 
in the organ weight changes and all changes remained 
within or at the limits of the normal historical ranges.
Macroscopic examination of organs and tissues at the 
end of the dosing period revealed occasional gross find-
ings that were considered to be either incidental or back-
ground conditions occurring sporadically or distributed 
evenly among all groups, including the control group. 
These included mechanical damage to the nails in males 
and females of all groups, lymph node enlargement in 
females of all groups, alopecia in one low-dose female, 
and ovary findings in one control female (cystic ovary) 
and one mid-dose female (hemorrhagic ovary). No gross 
findings  were  observed  following  the  recovery  period, 
with the exception of one high-dose male presenting with 
a hyperemic bladder filled with black flakes and stones, 
hydronephrosis, and atrophy of the left seminal vesicle. 
Similar  observations  were  not  noted  in  other  animals 
administered MK-7 examined following either the dosing 
or recovery period.
The  majority  of  histological  changes  noted  at  the 
end  of  the  dosing  period  were  incidental  or  common 
background findings that were also observed in control 
animals.  These  included  retinal  degeneration,  hepatic 
vacuolation, mild multifocal subacute or chronic inflam-
mation of the liver, heart, lungs, pancreas, urinary blad-
der, or prostate, mild multifocal subacute vacuolation of 
the adrenals, mild calculus of the urinary bladder, mild 
subacute pyelitis of the kidney, and focal thyroid cyst. 
Figure 3 shows histopathological pictures of major organs 
from control animals and animals treated with high dose, 
10 mg/kg/day MK-7.
Discussion
The physiological requirements for vitamin K are well-es-
tablished, and are typically met through dietary intake of 
vitamin K1 (phylloquinone) from plant sources. Vitamin 
K2 compounds, known as menaquinones, are less preva-
lent in the human diet than vitamin K1, but function in 
the same manner as vitamin K1 (Shearer and Newman, 
2008). Menaquinones are also associated with maintain-
ing,  in  particular,  normal  bone  health  (Binkley  et  al., 
2002; Knapen et al., 2007; Bügel, 2008; Shea and Booth, 
2008) and, therefore, are promoted for supplemental use. 
A novel synthetic MK-7 has been developed for human 
consumption and since no formal toxicological testing 
on MK-7 has, to our knowledge, been performed, stan-
dard toxicological tests were conducted. These included 
an acute toxicity study and a 90-day subchronic toxicity 
study  in  rodents  following  oral  administration  of  syn-
thetic MK-7.
The  results  of  the  acute  toxicity  study  demonstrate 
that MK-7 is of low acute toxicity in mice following oral 
exposure, with an LD50 of greater than 2000 mg/kg body 
weight. Subchronic oral exposure of Sprague-Dawley rats 
to MK-7 also did not produce any mortalities or clinical 
signs of systemic toxicity at doses of up to 10 mg/kg body 
weight/day,  including  any  significant  effects  on  body 
weights, body weight gains, or food consumption.
Compared with control values, significant, yet spo-
radic, increases in MCV and hematocrit were observed 
following  MK-7  administration,  but  remained  within 
Table 2.  Coagulation parameters in male and female rats following oral administration of menaquinone-7 (MK-7) in the 90-day 
subchronic toxicity study.
Parameter Study day
Malesa Femalesa
Control
2.5 mg/kg 
bw/d
5 mg/kg 
bw/d
10 mg/kg 
bw/d Control
2.5 mg/kg 
bw/d
5 mg/kg 
bw/d 10 mg/kg bw/d
Prothrombin 
time (sec)
Day 90 19.2 ± 1.4 19.2 ± 0.6 19.2 ± 1.2 19.0 ± 0.8 17.9 ± 0.7 18.5 ± 0.9 17.4 ± 1.0 17.2 ± 0.9
Day 121 (recovery) 20.9 ± 1.5 n/a n/a 20.0 ± 0.9 19.2 ± 1.3 n/a n/a 18.9 ± 0.6
APTT (sec) Day 90 19.4 ± 3.2 19.0 ± 3.2 19.0 ± 2.3 22.5 ± 5.1 19.3 ± 1.2 20.7 ± 1.6 22.6 ± 3.6* 23.6 ± 6.1*
Day 121 (recovery) 17.4 ± 3.1 n/a n/a 16.3 ± 1.8 17.3 ± 2.1 n/a n/a 17.1 ± 0.3
aOnly the control and high-dose (10 mg/kg bw/d) groups were included in the 30-day recovery period of the study.   All groups consisted 
of 10 animals, with the exception of the recovery groups (5 animals /group).
*Statistically significant different from the control group (P < 0.05).Synthetic vitamin K2, menaquinone-7, toxicology  527
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the normal ranges for Sprague-Dawley rats and were 
not associated with any other hematological changes 
related to anemia. These increases were thus considered 
incidental in nature without toxicological significance. 
Incidental  changes  in  the  clinical  chemistry  results 
were  similarly  observed,  with  no  consistent  changes 
indicative of a specific organ or toxicological effect. Such 
changes were also neither dose- nor time-dependent, 
were observed at only one time point and for the most 
part in one sex only, and were typically within the normal 
ranges. The few changes that were noted to lie above the 
normal ranges for Sprague-Dawley rats were observed in 
female rats at the mid-study point only and were consid-
ered to be at the limit of the normal physiological ranges 
Table 3.  Clinical chemistry parameters in male and female rats following oral administration of menaquinone-7 (MK-7) in the 90-day 
subchronic toxicity study.
Parameter
Study  
day
Malesa Femalesa
Control
2.5 mg/kg 
bw/d
5 mg/kg 
bw/d
10 mg/kg 
bw/d Control
2.5 mg/kg  
bw/d
5 mg/kg 
bw/d
10 mg/kg 
bw/d
A/G Day 44 1.3 ± 0.1 1.6 ± 0.1* 1.5 ± 0.2* 1.3 ± 0.1 1.5 ± 0.2 1.7 ± 0.1 1.9 ± 0.3* 1.5 ± 0.1
Day 90 1.2 ± 0.1 1.2 ± 0.1 1.2 ± 0.1 1.2 ± 0.1 1.4 ± 0.1 1.4 ± 0.1 1.4 ± 0.1 1.4 ± 0.2
ALB (g/L) Day 44 36 ± 4 42 ± 3 42 ± 6 36 ± 4 40 ± 6 46 ± 3 50 ± 5* 41 ± 4
Day 90 32 ± 2 32 ± 2 33 ± 2 31 ± 1 37 ± 2 38 ± 4 38 ± 3 38 ± 6
GLOB (g/L) Day 44 27 ± 1 27 ± 2 28 ± 1 27 ± 1 27 ± 1 27 ± 1 27 ± 1 28 ± 1
Day 90 28 ± 1 28 ± 1 27 ± 1 26 ± 2 27 ± 2 27 ± 2 27 ± 1 27 ± 1
ALP (U/L) Day 44 199 ± 59 180 ± 44 183 ± 44 164 ± 47 87 ± 13 136 ± 48 140 ± 31 119 ± 25
Day 90 117 ± 33 111 ± 23 111 ± 33 97 ± 28 62 ± 17 72 ± 28 63 ± 18 76 ± 17
Bil (T) (µmol/L) Day 44 3.1 ± 0.8 5.1 ± 2.2 5.3 ± 2.5 4.1 ± 2.1 2.7 ± 0.9 3.4 ± 1.1 5.4 ± 2.5 3.6 ± 1.0
Day 90 2.6 ± 0.6 2.9 ± 0.5 3.1 ± 1.2 2.9 ± 0.6 4.9 ± 1.2 4.9 ± 1.5 4.6 ± 0.8 4.5 ± 1.3
BUN (mmol/L) Day 44 3.9 ± 0.8 4.1 ± 1.3 3.9 ± 0.8 3.7 ± 0.6 3.7 ± 0.7 3.9 ± 0.7 4.6 ± 0.9 4.1 ± 0.3
Day 90 4.3 ± 0.9 4.6 ± 0.7 4.4 ± 0.7 4.3 ± 0.6 4.9 ± 0.7 5.1 ± 0.7 4.9 ± 0.4 5.0 ± 1.2
Ca (mmol/L) Day 44 2.64 ± 0.08 2.62 ± 0.08 2.55 ± 0.12 2.54 ± 0.09 2.69 ± 0.09 2.72 ± 0.06 2.86 ± 0.17 2.68 ± 0.16
Day 90 2.47 ± 0.08 2.53 ± 0.08 2.54 ± 0.08 2.50 ± 0.08 2.51 ± 0.06 2.53 ± 0.05 2.57 ± 0.06 2.56 ± 0.12
Cl (mmol/L) Day 44 102 ± 2 105 ± 2* 107 ± 2* 104 ± 1 104 ± 3 109 ± 2* 111 ± 3* 105 ± 2
Day 90 103 ± 2 103 ± 2 103 ± 1 104 ± 2 104 ± 1 105 ± 2 104 ± 2 105 ± 3
Creatinine 
(µmol/L)
Day 44 49 ± 11 53 ± 11 48 ± 15 41 ± 6 41 ± 7 44 ± 9 52 ± 17 39 ± 3
Day 90 44 ± 4 42 ± 3 41 ± 4 42 ± 3 44 ± 2 42 ± 3 41 ± 2 43 ± 2
Glucose 
(mmol/L)
Day 44 5.3 ± 0.7 7.6 ± 2.3* 6.4 ± 0.8 5.2 ± 0.7 5.5 ± 0.8 5.9 ± 0.4 5.9 ± 0.8 5.6 ± 0.6
Day 90 10.2 ± 2.1 11.4 ± 2.6 11.6 ± 2.2 10.3 ± 2.2 8.8 ± 1.9 10.5 ± 1.4* 8.8 ± 1.4 10.4 ± 1.5
LDH (U/L) Day 44 2487 ± 1487 2056 ± 721 2941 ± 1066 4904 ± 3338 1002 ± 443 2349 ± 959 1462 ± 419 2026 ± 996
Day 90 4837 ± 2285 3897 ± 2604 4783 ± 2201 3856 ± 2730 5496 ± 2219 2805 ± 1709* 3659 ± 1802 3168 ± 1735
P (mmol/L) Day 44 2.81 ± 0.46 3.02 ± 0.44 2.95 ± 0.69 2.48 ± 0.30 2.10 ± 0.26 2.25 ± 0.35 2.64 ± 0.74 2.08 ± 0.22
Day 90 2.03 ± 0.2 2.04 ± 0.19 2.15 ± 0.24 2.06 ± 0.16 1.78 ± 0.2 1.88 ± 0.24 1.87 ± 0.16 1.86 ± 0.23
K (mmol/L) Day 44 6.5 ± 0.9 6.9 ± 0.4 7.1 ± 1.2 6.0 ± 0.4 5.6 ± 0.9 6.1 ± 0.8 7.3 ± 1.4 6.0 ± 0.7
Day 90 5.2 ± 0.2 5.0 ± 0.4 5.1 ± 0.3 4.9 ± 0.3 4.6 ± 0.3 4.5 ± 0.4 4.5 ± 0.2 4.4 ± 0.3
Protein (T) 
(g/L)
Day 44 64 ± 4 70 ± 4 70 ± 7 63 ± 5 67 ± 6 73 ± 3 80 ± 8* 69 ± 5
Day 90 60 ± 2 60 ± 2 59 ± 3 57 ± 2* 64 ± 2 65 ± 4 65 ± 3 65 ± 7
AST (U/L) Day 44 84 ± 16 107 ± 21 102 ± 10 115 ± 23 69 ± 11 94 ± 19 87 ± 14 83 ± 13
Day 90 104 ± 25 109 ± 53 101 ± 19 105 ± 29 110 ± 30 83 ± 18* 89 ± 21 90 ± 12
ALT (U/L) Day 44 35 ± 4 43 ± 3 39 ± 9 42 ± 8 37 ± 4 38 ± 3 40 ± 12 41 ± 9
Day 90 40 ± 5 54 ± 42 42 ± 6 44 ± 9 36 ± 5 35 ± 11 35 ± 3 40 ± 7
Na (mmol/L) Day 44 145 ± 5 149 ± 4 153 ± 5 146 ± 3 145 ± 4 151 ± 5 158 ± 4* 146 ± 3
Day 90 141 ± 2 141 ± 1 142 ± 1 142 ± 1 141 ± 2 142 ± 2 142 ± 1 142 ± 2
Triglycerides 
(mmol/L)
Day 44 0.69 ± 0.28 0.93 ± 0.38 0.67 ± 0.21 0.66 ± 0.32 0.45 ± 0.09 0.49 ± 0.04 0.57 ± 0.24 0.45 ± 0.06
Day 90 0.72 ± 0.31 0.83 ± 0.39 0.65 ± 0.16 0.53 ± 0.11 0.50 ± 0.09 0.59 ± 0.12 0.53 ± 0.09 0.81 ± 0.42*
CK (U/L) Day 44 309 ± 150 534 ± 356 401 ± 93 531 ± 252 104 ± 26 301 ± 97 222 ± 163 182 ± 79
Day 90 454 ± 185 338 ± 221 416 ± 166 349 ± 182 481 ± 162 285 ± 168* 342 ± 152 247 ± 112*
Cholesterol 
(mmol/L)
Day 44 2.73 ± 0.27 2.79 ± 0.45 3.02 ± 0.52 2.31 ± 0.56 2.32 ± 0.60 2.81 ± 0.47 3.47 ± 0.86 2.93 ± 0.83
Day 90 2.43 ± 0.38 2.60 ± 0.66 2.54 ± 0.52 2.11 ± 0.46 2.48 ± 0.65 2.43 ± 0.67 2.64 ± 0.42 2.47 ± 0.86
GGT (U/L) Day 44 < 5 ± 0 < 5 ± 0 < 5 ± 0 < 5 ± 0 < 5 ± 0 < 5 ± 0 < 5 ± 0 < 5 ± 0
Day 90 < 5 ± 0 < 5 ± 0 < 5 ± 0 < 5 ± 0 < 5 ± 0 < 5 ± 0 < 5 ± 0 < 5 ± 0
ALB = albumin; ALP = alkaline phosphatase; ALT = alanine aminostranferase;  AST = aspartate aminotransferase; Bil = bilirubin; BUN = 
blood urea nitrogen; Ca = calcium; Cl = chloride; CK = creatine kinase; d = day; GGT = gamma-glutamyl transpeptidase; LDH = lactate 
dehydrogenase; K = potassium; P = phosphorus; LDH = lactate dehydrogenase; K = potassium; P = phosphorus.
*Statistically significant difference from control (P < 0.05).
aAll groups consisted of 10 animals.528  K. Pucaj et al.
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since  they  were  only  very  slightly  increased.  Various 
other hematology and clinical chemistry values, includ-
ing some control values, were also noted to lie outside of 
the normal ranges for Sprague-Dawley rats. These were 
also considered to be at the limit of the normal ranges 
since they were only very slightly outside of the normal 
ranges. A   compound-related effect could not be attrib-
uted to these observations, particularly given the lack of 
a dose- and/or time-dependent response.
Coagulation time in female rats appeared to be sig-
nificantly affected by MK-7 administration, with a sig-
nificant  increase  in  APTT  in  the  mid-  and  high-dose 
group compared with the control group at the end of the 
dosing period. The change in APTT was attributed to the 
elevated APTT times noted in two female rats in the mid-
dose group and one female rat in the high-dose group. 
Although this observed effect was most likely attribut-
able to suboptimal bleeding technique (as only a few 
animals were affected), the known role of vitamin K in 
coagulation was considered. In this regard, vitamin K is 
well-characterized as being required for blood coagula-
tion, which is inconsistent with an observed increase in 
clotting time. Furthermore, no significant effects of MK-7 
on PT were observed in either females or males, and PT 
and  APTT  remained  within  the  normal  physiological 
limits in all groups at the end of the dosing and recovery 
periods. Thus, the increase in APTT observed was not 
considered  to  be  compound-related  and  was  further 
not considered to be adverse in nature. Furthermore, 
studies  in  human  volunteers  demonstrate  that  natto-
derived  MK-7  has  no  effect  on  the  clotting  system  in 
healthy individuals. In this regard, single doses of up to 
1320 μg of MK-7/person had no effect on blood coagu-
lation  or  fibrinolytic  parameters  (thromboelastograph 
pattern, PT, and APTT) in six healthy men (Sumi, 1999). 
Likewise, no effects on coagulation (endogenous throm-
bin potential and thrombin peak height) were observed 
in healthy children following a daily intake of 45 μg of 
natto-derived  MK-7  for  8  weeks  in  a  double-blinded, 
randomized, placebo-controlled study (van Summeren 
et al., 2009). Large doses of MK-7, however, may interact 
with anticoagulant therapies that are vitamin K antago-
nists as demonstrated by Schurgers et al. (2007), and 
therefore vitamin K2 supplementation should be limited 
in patients on oral anticoagulants.
At the end of the dosing period, organ weight changes 
were limited to female rats administered MK-7, and con-
sisted of a decrease in ovary weights in the mid-dose group 
and an increase in lung weight relative to brain weight in 
the high-dose group compared with the control group. 
ABC
DE
GH
F
Figure 3.  Histopathological pictures of major organs from control animals (A–D) and animals treated with high dose, 10 mg/kg/day 
menaquinone-7 (MK-7) (E–H). All photos are 10× magnification and all the tissues are considered to be without histopathological findings. 
Control male rats (10×): renal cortex (A), spleen (B), liver (C), and cerebral cortex (D). MK-7 10 mg/kg/day male rats (10×): renal cortex (E), 
spleen (F), liver (G), and cerebral cortex (H).Synthetic vitamin K2, menaquinone-7, toxicology  531
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These significant differences were not dose-dependent 
and  values  were  typically  within  the  normal  ranges. 
Moreover, no compound-related effects were identified 
in these or other organs upon macroscopic and histologi-
cal examination that would be indicative of toxicity. All 
gross and histological findings were incidental or com-
mon background findings that occurred sporadically or 
were distributed evenly among all groups, including the 
control group.
Based on the results of the subchronic toxicity study, 
oral administration of MK-7 does not produce adverse 
effects in Sprague-Dawley rats at doses of up to 10 mg/
kg body weight/day. Thus, the no observed adverse effect 
level (NOAEL) for synthetic MK-7 in Sprague-Dawley rats 
is  10 mg/kg  body  weight/day,  the  highest  dose  tested. 
Considering  that  supplemental  vitamin  K  is  provided 
at doses in the microgram range, typically 25 to 100 μg/
person/day (Physician’s Desk Reference, 2008), there is a 
large margin of safety with synthetic MK-7.
Although no other standard toxicological tests have 
been identified from the scientific literature that specifi-
cally address the safety of MK-7, rat studies investigating 
the effect of natto-derived MK-7 on bone health have been 
performed and support the general findings of the pres-
ent investigation. For instance, dietary administration of 
MK-7 at a concentration of 18 mg/100 g diet, equivalent to 
~14 mg/kg body weight/day, for 24 days had no adverse 
effects  on  body  weights,  femoral  dry  weight,  or  other 
parameters  of  bone  health  in  ovariectomized  female 
Wistar rats (Yamaguchi et al., 1999). Similar results were 
observed in female-ovariectomized Wistar rats fed diets 
containing natto, providing 9.4 μg MK-7/100 g diet, and 
supplemented with or without MK-7 for a total of 9.4, 
14.1, 18.8, or 37.6 μg MK-7/100 g diet for periods of 24 to 
150 days (Yamaguchi et al., 1999, 2000).
The low oral toxicity of MK-7 is supported by the results 
of repeated-dose oral toxicity studies conducted on the 
MK-7  analog  MK-4.  Such  studies  include  subchronic 
(13-week) and chronic (1-year) oral toxicity studies con-
ducted in rats and dogs. The NOAEL for MK-4 in dogs was 
determined  to  be  200 mg/kg  body  weight/day  in  both 
the 13-week and 1-year studies (Goldsmith et al., 1995; 
Vanatta et al., 1995). Although no adverse effects were 
observed in rats orally administered 30 mg MK-4/kg body 
weight/day for 13 weeks (Doi et al., 1995), the decrease 
in PT in males rats in the 1-year study (Hosokawa et al., 
1995) may be viewed as a potential adverse effect, with a 
lowest observed adverse effect level (LOAEL) of 20 mg/kg 
body weight/day, the lowest dose tested. This value, how-
ever, still allows for a large margin of safety for menaqui-
nones given the typical supplemental doses of vitamin 
K and taking into consideration that a NOAEL of 10 mg/
kg body weight/day has been determined for synthetic 
MK-7 in the present investigation. Furthermore, similar 
effects on blood coagulation have not been observed in 
healthy humans as noted above.
Although  not  prevalent  in  the  normal  human  diet, 
natural dietary sources of MK-7 include certain cheeses, 
pork, certain fish, and sauerkraut (Schurgers and Vermeer, 
2000). The most abundant dietary source of MK-7, how-
ever, is natto, a traditional Japanese food, which contains 
~1 mg MK-7/100 g (Schurgers and Vermeer, 2000). Thus, 
there is a history of human consumption of MK-7, sup-
porting the general safety of this vitamin K2 compound 
in  humans.  Moreover,  natto-derived  MK-7  has  been 
authorized for use in foods for particular nutritional uses, 
food supplements, and foods intended for the general 
population in the European Union (EFSA, 2008).
In  summary,  the  results  of  the  present  investiga-
tion  demonstrate  that  synthetic  MK-7  is  of  low  acute 
oral  toxicity,  with  a  median  lethal  dose  (LD50)  above 
2000 mg/kg  mice.  Furthermore,  the  NOAEL  for  MK-7 
in Sprague-Dawley rats was considered to be 10 mg/kg 
body weight/day, the highest dose tested, based on lack 
of adverse effects observed in the 90-day oral toxicity 
study. Together with the known history of consumption 
of natto-derived MK-7 and other menaquinone analogs, 
these data support the safety of a synthetically derived 
MK-7 for human consumption at typical supplemental 
doses of vitamin K.
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